Understanding DHODH Inhibition
Therapeutic Mechanisms of Action of JBZ-001
On top of the expected nucleotide depletion-induced cell stress, our DHODH inhibitor, JBZ-001, displays multiple mechanisms of action, broadening its potential clinical applications, including:
Explore JBZ-001’s Therapeutic Effects:
Biological Effect
Widescale Metabolic Disruption
JBZ-001 inhibits the de novo synthesis of pyrimidine nucleotides, effectively shutting down the cell’s ability to produce these essential building blocks. This disruption leads to significant metabolic stress, ultimately triggering widespread cellular dysfunction and cell death.
Combination Therapy Potential
Excellent single agent and combination therapeutic efficacy
JBZ-001 demonstrates potent single-agent activity against various preclinical cancer models, including patient-derived leukemia cells. Importantly, our preclinical data suggests JBZ-001 synergizes effectively with other anti-leukemia treatments such as 5-Azacytidine and Venetoclax, offering a powerful combination strategy for treating leukemia. View our pipeline.
To learn more, explore our preclinical data > here.
To learn more, explore our preclinical data > here.